Organoids as Next-Generation Models for Tumor Heterogeneity, Personalized Therapy, and Cancer Research: Advancements, Applications, and Future Directions
Organoids · 08.10.2025 · 4 (4) · 23
DOI: 10.3390/organoids4040023 ↗Kurz gefasst
Fachartikel in der Zeitschrift Organoids, online erschienen am 08.10.2025. Verfasst von Ayush Madan und 4 weiteren Autor:innen. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 216 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Organoid technology has emerged as a revolutionary tool in cancer research, offering physiologically accurate, three-dimensional models that preserve the histoarchitecture, genetic stability, and phenotypic complexity of primary tumors. These self-organizing structures, derived from adult stem cells, induced pluripotent stem cells, or patient tumor biopsies, recapitulate critical aspects of tumor heterogeneity, clonal evolution, and microenvironmental interactions. Organoids serve as powerful systems for modeling tumor progression, assessing drug sensitivity and resistance, and guiding precision oncology strategies. Recent innovations have extended organoid capabilities beyond static culture systems. Integration with microfluidic organoid-on-chip platforms, high-throughput CRISPR-based functional genomics, and AI-driven phenotypic analytics has enhanced mechanistic insight and translational relevance. Co-culture systems incorporating immune, stromal, and endothelial components now permit dynamic modeling of tumor–host interactions, immunotherapeutic responses, and metastatic behavior. Comparative analyses with conventional platforms, 2D monolayers, spheroids, and patient-derived xenografts emphasize the superior fidelity and clinical potential of organoids. Despite these advances, several challenges remain, such as protocol variability, incomplete recapitulation of systemic physiology, and limitations in scalability, standardization, and regulatory alignment. Addressing these gaps with unified workflows, synthetic matrices, vascularized and innervated co-cultures, and GMP-compliant manufacturing will be crucial for clinical integration. Proactive engagement with regulatory frameworks and ethical guidelines will be pivotal to ensuring safe, responsible, and equitable clinical translation. With the convergence of bioengineering, multi-omics, and computational modeling, organoids are poised to become indispensable tools in next-generation oncology, driving mechanistic discovery, predictive diagnostics, and personalized therapy optimization.
Zitieren
APA
Madan, A., Saini, R., Dhiman, N., Juan, S., & Satapathy, M. K. (2025). Organoids as Next-Generation Models for Tumor Heterogeneity, Personalized Therapy, and Cancer Research: Advancements, Applications, and Future Directions. Organoids, 4(4), 23. https://doi.org/10.3390/organoids4040023
Vancouver
Madan A, Saini R, Dhiman N, Juan S, Satapathy MK. Organoids as Next-Generation Models for Tumor Heterogeneity, Personalized Therapy, and Cancer Research: Advancements, Applications, and Future Directions. Organoids. 2025;4(4):23. doi:10.3390/organoids4040023
BibTeX
@article{Madan2025,
author = {Madan, Ayush and Saini, Ramandeep and Dhiman, Nainci and Juan, Shu-Hui and Satapathy, Mantosh Kumar},
title = {Organoids as Next-Generation Models for Tumor Heterogeneity, Personalized Therapy, and Cancer Research: Advancements, Applications, and Future Directions},
journal = {Organoids},
year = {2025},
volume = {4},
number = {4},
pages = {23},
doi = {10.3390/organoids4040023}
}
EUVIMED